EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 3.0

Nivolumab in Relapsed or Refractory Primary Central Nervous System Lymphoma: Multicenter, Retrospective Study

Jun Ho Yi, Seok Jin Kim, Sang-A Kim, Jongheon Jung, Dok Hyun Yoon

Cancer Research and Treatment · 2025

DOI: 10.4143/crt.2024.531 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Jun Ho Yi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Seoul, Korea. Hauptthemen laut MEDLINE: Nivolumab, Central Nervous System Neoplasms, Immune Checkpoint Inhibitors, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Given that 40%-50% of primary central nervous system lymphoma (PCNSL) tissues exhibit aberrancy on 9p24.1, immune checkpoint inhibitors (ICI) may work for the disease.Materials and Methods To define the role of ICIs in PCNSL, we carried out a nationwide retrospect analysis for 22 patients who had been treated with nivolumab monotherapy for relapsed or refractory PCNSL.

Results

The median age at diagnosis was 66, and male: female ratio was 1:1. Patients received nivolumab after a median of 3 lines (range, 2 to 6) of therapy and at the median age of 67 years (range, 37 to 82 years). Eleven patients (50%) were refractory to the last treatment prior to nivolumab. With a median follow-up duration of 22.3 months (95% confidence interval [CI], 13.1 to 31.5), nine patients (41%) had an objective response (6 complete responses, 3 partial responses), and the median duration of response was 20.9 months (95% CI, 1.7 to 40.0). The median progression-free survival and overall survival were 2.1 months (95% CI, 0.2 to 4.0) and 18.9 months (95% CI, 5.0 to 32.8), respectively. Nivolumab was generally well-tolerated as no patients required dose reduction and only two patients required delay of treatment.

Conclusion

Our study suggests that nivolumab can be a reasonable option with the durable response for RR PCNSL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabCentral Nervous System NeoplasmsImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalAntineoplastic Agents, ImmunologicalLymphomaHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAdultAged, 80 and overTreatment OutcomeDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Immune checkpoint inhibitorNivolumabPrimary CNS lymphoma

Substanzen

NivolumabImmune Checkpoint InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Seoul, Korea.
  • Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University, Seongnam, Korea.
  • Center for Hematologic Malignancies, National Cancer Center, Goyang, Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Zitieren

APA

Yi, J. H., Kim, S. J., Kim, S. A., Jung, J., & Yoon, D. H. (2025). Nivolumab in Relapsed or Refractory Primary Central Nervous System Lymphoma: Multicenter, Retrospective Study. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.531

Vancouver

Yi JH, Kim SJ, Kim SA, Jung J, Yoon DH. Nivolumab in Relapsed or Refractory Primary Central Nervous System Lymphoma: Multicenter, Retrospective Study. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.531

BibTeX
@article{Yi2025,
  author = {Yi, Jun Ho and Kim, Seok Jin and Kim, Sang-A and Jung, Jongheon and Yoon, Dok Hyun},
  title = {Nivolumab in Relapsed or Refractory Primary Central Nervous System Lymphoma: Multicenter, Retrospective Study},
  journal = {Cancer Research and Treatment},
  year = {2025},
  doi = {10.4143/crt.2024.531}
}
Kostenlos starten →